Thermo Fisher Scientific (PRNewsfoto/Thermo Fisher Scientific)
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of an active pharmaceutical ingredient (API) manufacturing facility from GlaxoSmithKline (GSK) for €90 million. Completion of the transaction follows the receipt of all required regulatory approvals.
Approximately 400 employees at the Cork, Ireland, site will become part of Thermo Fisher’s Pharma Services business within its Laboratory Products and Services Segment.
Date: October 07, 2019
Source: PR Newswire
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
